7 MiMedx Group Analyst Ratings, Earnings, Dividends and Insider Trades | $MDXG | NASDAQ:MDXG | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact MiMedx Group Company Profile (NASDAQ:MDXG) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for MiMedx Group (NASDAQ:MDXG) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 2 Hold Rating(s), 1 Buy Rating(s)Consensus Rating:Hold (Score: 2.33)Consensus Price Target: $9.00 (24.48% upside) Analysts' Ratings History for MiMedx Group (NASDAQ:MDXG) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare1/6/2014Northland Capital PartnersDowngradeOutperform -> Market Perform$6.00View 1/6/2014Northland SecuritiesDowngradeOutperform -> Market PerformView 12/20/2013Canaccord GenuityBoost Price Target$12.00View 11/1/2013Northland Capital PartnersBoost Price TargetOutperform$5.00 -> $6.00View 10/31/2013Canaccord GenuityBoost Price TargetBuy$6.00 -> $6.50View 10/4/2013Canaccord GenuityInitiated CoverageBuy$6.00View 9/6/2013Northland Capital PartnersLower Price TargetOutperform$7.00 -> $5.00View 8/20/2013Lake Street CapitalInitiated CoverageBuyView 8/2/2013Northland Capital PartnersBoost Price TargetOutperform$6.00 -> $7.00View 1/4/2013Northland SecuritiesInitiated CoverageOutperform$5.00View 1/4/2013Northland SecuritiesInitiated CoverageOutperform$5.00View 11/19/2012Craig HallumInitiated CoverageBuy$5.00View (Data available from 3/11/2012 forward) Earnings History for MiMedx Group (NASDAQ:MDXG)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/26/2014Q4($0.01)($0.04)$18.31 million$18.00 millionViewListenView 7/31/2013Q2 2013($0.01)($0.01)$12.94 million$13.52 millionViewListenView 5/1/2013Q1 2013($0.02)($0.02)$11.34 million$11.56 millionViewListenView (Data available from 1/1/2011 forward) Dividend History for MiMedx Group (NASDAQ:MDXG)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for MiMedx Group (NASDAQ:MDXG)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare1/17/2014Parker PetitCEOSell150,000$8.28$1,242,000.00View 8/28/2013William Charles TaylorCOOSell9,800$6.15$60,270.00View 8/7/2013William Charles TaylorCOOSell183,765$6.21$1,141,180.65View 5/16/2013Steve GorlinDirectorSell30,000$6.46$193,800.00View (Data available from 1/1/2013 forward) About MiMedx Group MiMedx Group, Inc. is a development-stage company. The Company is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane. As of December 31, 2011, the Companyâ€™s biomaterial platform technologies include the device technologies HydroFix and CollaFixTM, and our tissue technologies, AmnioFix and EpiFix. business was conducted by its three divisions: MiMedx, Inc. (MiMedx), SpineMedica, LLC (SpineMedica) and Level Orthopedics. The Company operates in one business segment, regenerative biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Orthopedics, Spine, Ophthalmic and Dental market categories. In January 5, 2011, the Company acquired Surgical Biologics, LLC. Headlines: (2/26) MiMedx Announces Record 2013 Results (3/4) MiMedx To Present At 2014 Canaccord Genuity Musculoskeletal Conference (2/25) MiMedx Sponsored Osteoarthritis Study Using PURION® Processed Amniotic Tissue Published In Arthritis Research & Therapy (2/25) Second MiMedx EpiFix® Randomized Comparative Study Published In International Wound Journal Shows 92.5% Healing Rate ... (2/12) MiMedx EpiFix® Allograft Awarded Coverage by HCSC (2/10) MiMedx EpiFix® Allograft Receives Reimbursement Coverage From The 7th Of The 8 Medicare Contractors (2/26) MiMedx Group Inc. misses by $0.03, misses on revenue Industry, Sector and Symbol: Sector: N/A Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: MDXG CUSIP: Key Metrics: Previous Close: $7.2350 Day Moving Average: $7.3832200 Day Moving Average: $6.3346 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $764.4MCurrent Quarter EPS Consensus Estimate: $-0.01 EPS Additional Links: View MDXG on Google FinanceView MDXG on Yahoo FinanceView MDXG's Company Profile on ReutersSearch for MiMedx Group on Google MiMedx Group (NASDAQ:MDXG) Chart for Tuesday, March, 11, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.